Background: Bone sialoprotein (BSP) interacts separately with both matrix metalloproteinase 2 (MMP-2) and integrin αvβ 3 and is overexpressed in many metastatic tumors. Its role in tumor biology, however, remains unclear. We investigated whether BSP enhances cancer cell invasiveness by forming a trimolecular complex with MMP-2 and cell-surface integrin αvβ 3. Methods: Invasiveness of breast, prostate, lung, and thyroid tumor cell lines was measured with a modified Boyden chamber assay. Binding and co-localization of BSP, MMP-2, and integrin α vβ3 were investigated with immunoprecipitation and in situ hybridization. All statistical tests were two-sided. Results: Treatment with BSP increased invasiveness of many breast, prostate, lung, and thyroid cancer cells through Matrigel in a dose-dependent manner. BSP at 50 nM increased the invasiveness of SW-579 thyroid cancer cells (95.2 units, 95% confidence interval [CI] = 90.4 to 100 units) by approximately 10-fold compared with that of untreated control SW-579 cells (9.1 units, 95 % CI = 5.7 to 12.5 units) (P
CITATION STYLE
Karadag, A., Ogbureke, K. U. E., Fedarko, N. S., & Fisher, L. W. (2004). Bone sialoprotein, matrix metalloproteinase 2, and α vβ3 integrin in osteotropic cancer cell invasion. Journal of the National Cancer Institute, 96(12), 956–965. https://doi.org/10.1093/jnci/djh169
Mendeley helps you to discover research relevant for your work.